Lateral-Flow Device for Diagnosis of Fungal Infection
- 285 Downloads
Invasive aspergillosis (IA) is a life-threatening complication of haematological malignancy and haematopoietic stem cell transplantation caused by the ubiquitous fungus Aspergillus. Current diagnosis of IA is multifaceted relying on data from clinical, radiological, and microbiological sources. The detection of Aspergillus biomarkers provides strategies both to pre-empt and to exclude disease, but the choice of biomarker assays is limited, requiring specialist equipment and training. This review examines recent advances in the accurate diagnosis of IA through the development of an Aspergillus lateral-flow device (LFD) incorporating a monoclonal antibody, JF5, which detects an antigenic marker of active infection. Recent trials using bronchoalveolar lavage fluids and serum samples from humans and from animal models of disease, have demonstrated the utility of the LFD as a rapid and user-friendly adjunct test for the quick and accurate diagnosis of pulmonary infections.
KeywordsAspergillus Aspergillosis Candida Cryptococcus β-glucan Galactomannan Hybridoma technology Monoclonal antibody Lateral-flow device
The comments and conclusions in this report are the thoughts and observations of the author.
Conflict of Interest
The author developed the Aspergillus monoclonal antibody JF5 and the Aspergillus LFD described in this article, and is the CEO, Technical Director, and a shareholder of the University of Exeter spin-out company ISCA Diagnostics Limited, which has been granted patents, and may receive royalties for the products listed above.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.• Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22(3):447–65. A contemporary review of the biology of A. fumigatus, airway colonization, adaptation to the mammanlian lung environment and its interaction with cells of the immune system.PubMedCrossRefGoogle Scholar
- 5.Ainsworth GC: Aspergillosis. In Introduction to the history of medical and verterinary mycology. Cambridge University Press; 2002:47–9.Google Scholar
- 12.• Barton R, (2013). Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction to outcome. Scientifica, Hindawi Publishing Corporation. Available at http://www.hindawi.com/journals/scientifica/2013/459405/Accessed January 2013. A comprehensive review of the laboratory diagnosis of invasive aspergillosis.
- 13.Thornton CR. Detection of Invasive Aspergillosis. Adv Appl Microbiol. 2008;7:187–216.Google Scholar
- 14.•• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. This article defines the diagnostic criteria needed to establish possible, probable, or proven invasive fungal disease, and is a revised version of the 2002 consensus group guidelines.PubMedCrossRefGoogle Scholar
- 15.•• White PL, Parr C, Thornton C, et al. An evaluation of real-time PCR, galactomannan ELISA and a novel lateral-flow device for diagnosis of invasive aspergillosis. 2013;51:1510–16. A large-scale evaluation of LFD diagnosis of IA, using serum from haematological patients, and comparison of assay sensitivity and specificity as a stand-alone test or when used in combination with commercial GM-EIA and PCR assays.Google Scholar
- 16.• Thornton CR, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp. 2012;61:e3721. An open-access video journal demonstrating the mechanics of the Aspergillus LFD, serum and BALf preparation, and interpretation of test results using human BALf samples.Google Scholar
- 22.•• Hoenigl M, Koidl C, Duettman W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect. 2012;65:588–91. LFD detection of IA using human BALf samples and its performance compared to the commercial Platelia GM-EIA.PubMedCrossRefGoogle Scholar
- 48.Percival A, Thorkildson P, Kozel TR. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcocus neoformans, reduce serotype bias in immunoassay for cryptococcal antigen. Clin Vacc Immunol. 2011;18:1292–6.CrossRefGoogle Scholar
- 50.•• Wiederhold NP, Najvar LK, Bocanegra R, et al. Inter-Laboratory and Inter-Study Reproducibility of a Novel Lateral-Flow Device and the Influence of Antifungal Therapy on the Detection of Invasive Pulmonary Aspergillosis. J Clin Microbiol. 2013;51:459–65. A study using serum and BALf from an established animal model of IA, comparing the LFD, and commercial GM-EIA and β-glucan tests for disease diagnosis and the effect of antifungal treatments on assay sensitivities.PubMedCrossRefGoogle Scholar
- 53.Vanselow M, Brandt ME, Park BJ. Diagnosis and management of Cryptococcal disease in resource-limited settings. Curr Fungal Infect Rep. 2012;Google Scholar
- 57.Thornton CR, Wills O. Immunodetection of fungal and oomycete pathogens: established and emerging threats to human health, animal welfare and global food security. Crit Rev Microbiol. 2013, in press.Google Scholar